HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study

HAIC every 3 weeks until 6 treatments have been completed, or HAIC therapy is terminated if patients have not reached 6 treatments and experience intolerable adverse effects; adebrelimab, fixed dose 1200 mg, IV, D1, every 21 days (Q3W), in combination with apatinib, 250 mg (0.25 g), orally, once daily (QD), consecutively dosing in 3-week (21-day) treatment cycles. Study treatment will continue until the subject develops an intolerable toxic reaction, withdraws informed consent, and progresses according to RECIST v1.1 as confirmed by the investigator (after the subject develops disease progression as defined by RECIST v1.1, if the investigator assesses that the subject is still clinically beneficial and can tolerate the study treatment, the subject may continue to receive the study drug; if it is considered that the subject no longer has clinical benefit, then treatment may be terminated), or other termination criteria specified in the protocol, whichever occurs first.